Catalyst stock slumps ~20% as Teva seeks FDA approval of generic Firdapse

Building of Teva Canada Markham manufacturing facility.

JHVEPhoto/iStock Editorial via Getty Images

Catalyst Pharmaceuticals (NASDAQ:CPRX) said Teva Pharmaceuticals (NYSE:TEVA) submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval to make and sell a generic version of Catalyst’s medicine Firdapse in the U.S.


Source link

5 Trading strategies to make money

Looking to boost your trading profits?

Get you copy of our FREE Ebook Now !!!